Journey Medical Corporation — FY2023 Form 10-K
Business context and reporting period. Journey Medical is a commercial-stage pharmaceutical company focused on dermatology products, with seven branded and two authorized-generic prescription products marketed in the U.S. This filing covers the fiscal year ended December 31, 2023, compared with FY2022; it does not provide separate Q4 results. Journey is majority-owned by Fortress Biotech.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue | $79.2 million | $73.7 million |
| Net product revenue | $59.7 million | $71.0 million |
| Other revenue | $19.5 million | $2.7 million |
| Operating loss | $2.1 million | $27.5 million |
| Net loss | $3.9 million | $29.6 million |
| Loss per share, basic and diluted | $0.21 | $1.69 |
| Net cash from (used in) operating activities | $5.2 million | $(13.5) million |
| Cash and cash equivalents at year-end | $27.4 million | $32.0 million |
| Term-loan principal at year-end | $15.0 million | — |
Product revenue less product cost of goods sold implies a product gross margin of approximately 55.3% in FY2023, versus 56.7% in FY2022; this is a simple calculation from the filing’s figures. The filing does not present a consolidated gross-margin measure that includes other revenue. Year-end current assets were $56.5 million and current liabilities $41.9 million, a current ratio of approximately 1.35. Total liabilities were $56.5 million and stockholders’ equity $20.4 million.
Material changes versus FY2022
- Total revenue rose 7%, but net product revenue fell 16%. The increase in total revenue principally reflects Maruho’s $19.0 million non-refundable upfront payment for Qbrexza licensing rights in Asian territories.
- Product revenue declined for Targadox (60%), Ximino (94%), Exelderm (31%), Amzeeq (14%), Zilxi (14%) and Qbrexza (5%). Accutane revenue grew 10% to $20.2 million. Ximino sales were discontinued in September 2023.
- Operating expenses fell 20%, including a 26% reduction in selling, general and administrative expense following sales-force headcount reductions and marketing and other cost cuts. Research and development expense declined 31% as DFD-29 trials wound down.
- Journey recorded a $3.1 million non-cash impairment of the Ximino intangible asset. Operating and net losses narrowed substantially from FY2022, but the company remained loss-making.
- Operating cash flow improved to $5.2 million, primarily due to the lower net loss and Maruho payment, alongside changes in working capital. Cash declined by $4.6 million during the year.
Outlook, risks and notable items
- Going concern: Management and the auditor report substantial doubt about Journey’s ability to continue as a going concern for at least 12 months from issuance of the financial statements. The statements are prepared on a going-concern basis and include no adjustments for the outcome of this uncertainty. Management says additional financing may be needed; availability and terms are not assured.
- DFD-29: Two Phase 3 trials reported positive topline results in 2023. Journey filed an NDA on January 4, 2024 and paid a $4.0 million filing fee. The FDA accepted the NDA on March 18, 2024, with a PDUFA goal date of November 4, 2024. Journey expects potential approval in the second half of 2024, subject to FDA review. A $3.0 million milestone payment to Dr. Reddy’s was due in April 2024 following NDA acceptance.
- Debt: In December 2023, Journey borrowed $15.0 million under a SWK facility of up to $20.0 million; the remaining $5.0 million may be drawn within 12 months. The loan matures December 27, 2027, bears quarterly-reset interest at three-month SOFR (5% floor) plus 7.75%, and is secured by substantially all company assets. Principal payments generally begin in February 2026. A revenue threshold may defer amortization to February 2027. The filing reports compliance with financial covenants at year-end.
- Contractual and financing needs: The company disclosed $3.0 million of Ximino installment payments classified as current, as well as potential DFD-29 milestones of up to $158.0 million and sales-based royalties. Future obligations also include royalties and product-acquisition milestones. Journey may seek additional debt or equity financing; equity issuance could dilute shareholders.
- Key business risks: Product sales face generic and branded competition, reimbursement and rebate pressure, and reliance on third-party manufacturers, suppliers, distributors and CROs. Accutane, Targadox and Exelderm lack patent protection. DFD-29 approval and commercialization are uncertain.
- Cybersecurity incident: A 2021 incident caused approximately $9.5 million in misdirected wire transfers. The FBI investigation remained ongoing; the company said the government traced and seized associated cryptocurrency and expected a process to return funds, but the amount and timing of recovery were uncertain.
- Governance and audit: Fortress controls the company’s voting majority. KPMG issued an unqualified opinion on the financial statements, while highlighting the going-concern uncertainty. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness because Journey is an emerging growth company.
Important facts for investors to verify
- Whether operating cash generation can be sustained as the $19.0 million Maruho upfront payment is non-recurring and product revenue declined.
- Cash runway, financing plans and compliance with SWK revenue and liquidity covenants; confirm whether Journey drew the remaining $5.0 million.
- FDA review progress for DFD-29, the November 4, 2024 PDUFA date, and payment of the $3.0 million milestone.
- Product-level sales, gross-to-net deductions and reserves, especially managed-care rebates, coupons and returns.
- Status and timing of the Ximino installment obligation and other contingent milestones, royalties and debt repayment requirements.
- Recovery, if any, of the 2021 cyber-fraud funds, and any material updates to the going-concern assessment.